<?xml version="1.0" encoding="UTF-8"?>
<p>CQ and HCQ are reported to have strong antiviral property for SARS-CoV 
 <italic>in vitro</italic>. Similar to COVID-19, CQ interferes with glycosylation of cellular receptor ACE2 of SARS-CoV.
 <sup>
  <xref rid="bibr30-1759720X20947296" ref-type="bibr">30</xref>
 </sup> Interestingly, the inhibitory effect was noted before and after viral entry, which means CQ may offer benefit for both prophylaxis and treatment.
 <sup>
  <xref rid="bibr31-1759720X20947296" ref-type="bibr">31</xref>,
  <xref rid="bibr32-1759720X20947296" ref-type="bibr">32</xref>
 </sup>
</p>
